Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Kaaijk, Patricia ^a   van der Ende, Arie ^b   Berbers, Guy ^a   van den Dobbelsteen, Germie P J M ^a   Rots, Nynke Y ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; DISEASE SURVEILLANCE; DOSE RESPONSE; HOST RESISTANCE; HUMAN; INFECTION PREVENTION; INFECTION RESISTANCE; MENINGOCOCCOSIS; NETHERLANDS; SINGLE DRUG DOSE; TREATMENT OUTCOME; ADOLESCENT; ADULT; CHILD; EPIDEMIC MENINGITIS; FEMALE; HEALTH SERVICES RESEARCH; IMMUNIZATION; IMMUNOLOGY; INFANT; MALE; METHODOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MIDDLE AGED; NETHERLANDS; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84857800266     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-35     Document Type: Article

References (20)

1. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011, 7:170-182. 10.4161/hv.7.2.13717, 3166476, 21178398.
2. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. Vaccines 2008, 399-434. Saunders, Elsevier, Plotkin SA, Orenstein WA, Offit PA, 5.
3. Chiappini E, Venturini E, Bonsignori F, Galli L, de Martino M. Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr 2010, 99:1609-1614. 10.1111/j.1651-2227.2010.01908.x, 20545931.
4. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007, 31:101-107. 10.1111/j.1574-6976.2006.00053.x, 17168998.
5. Bacterial Meningitis in the Netherlands. Annual reports 2000-2009. , http://www.amc.uva.nl/?pid=8446
6. de Greeff CS, de Melker HE, Schouls LM, Spanjaard L, van Deuren M. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 20032005. Eur J Clin Microbiol Infect Dis 2008, 27:985-992. 10.1007/s10096-008-0535-1, 18493804.
7. Lier van EA, et al. RIVM Rapport 210021011 Vaccinatiegraad Rijksvaccinatieprogramma Nederland. 2010, , http://www.rivm.nl/bibliotheek/rapporten/210021011.pdf
8. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743. 10.1086/527401, 18271745.
9. de Voer RM, Mollema L, Schepp RM, de Greeff SC, van Gageldonk PG, de Melker HE, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal C conjugate vaccine. PLoS One 2010, 5:e12144. 10.1371/journal.pone.0012144, 2921331, 20730091.
10. de Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 1998, 121:637-643. 10.1017/S0950268898001587, 2809572, 10030714.
11. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 2009, 67:301-308.
12. Snape MD, Kelly DF, Lewis S, Banner C, Kibwana L, Moore CE, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336:1487-1491. 10.1136/bmj.39563.545255.AE, 2440906, 18535032.
13. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786. 193909, 12965904.
14. Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu LM, et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008, 180:2165-2173.
15. Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006, 43:1387-1394. 10.1086/508776, 17083009.
16. de Voer RM, van der Klis FR, Engels CW, Schepp RM, van de Kassteele J, Sanders EA, et al. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults. Vaccine 2009, 27:6974-6982. 10.1016/j.vaccine.2009.09.082, 19800445.
17. Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun 2003, 71:5549-5555. 10.1128/IAI.71.10.5549-5555.2003, 201087, 14500473.
18. Joint Committee on Vaccination and Immunisation DoH, England. Proposed changes to the routine childhood immunisation schedule. 2005, , http://www.advisorybodies.doh.gov.uk/jcvi/childhoodimmunisationoc05.pdf
19. De Wals P, Trottier P, Pépin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 2006, 24:3500-3504. 10.1016/j.vaccine.2006.02.010, 16517032.
20. Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007, 137(Suppl 1):S4-9.